Tianxin Pharmaceutical (603235.SH) released its performance for the first half of the year, with a net profit attributable to shareholders of 3.56 billion yuan, representing a 3.14% increase.

China Fortune Finance App news, Tianxin Pharmaceutical (603235.SH) released its 2025 interim report. The company's operating income was 1.122 billion yuan, an increase of 5.23% year-on-year. Net profit attributable to shareholders of the listed company was 356 million yuan, an increase of 3.14% year-on-year. Net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 336 million yuan, an increase of 2.15% year-on-year. Basic earnings per share were 0.82 yuan.